Philadelphia PA (PRWEB) November 23, 2015
Olfactory Biosciences Corp. (OLFC) (OTC Markets ) is pleased to report that Sensopath™, a topical gel preparation for autism spectrum disorder (ASD) and related information integration issues were the Best-Selling OLFC product of the year. Feedback from customers was extremely positive with many reorders. The Sensopath™ preparation is made with natural ingredients and is effective using advanced olfaction and chemoreception. Applying Sensopath™ topical medicine is just rubbing a small amount of the gel to the end of your nostrils. https://noxoinfo.com/product2015/
Many people have difficulty processing everyday sensory information; this is usually called having Sensory Integration Difficulties such as those with an Autism Spectrum Disorder (ASD). Sensopath™ can have a beneficial effect on these sensory issues.
Sensopath™ may also improve moderate attention deficits like ADD or ADHD since molecules transport their “messages” directly to the brain’s limbic system for improved focus and attention. Olfactory receptors are nerves and neurotransmitters and act by attaching to the company's natural ingredients.
Sensopath™ also has a beneficial effect on a highly sensitive person (HSP). A highly sensitive person is someone who has high sensory processing and an “innate sensitiveness.” About 20 percent of the population is believed to be highly sensitive. https://noxoinfo.com/product2015/
Each Sensopath™ preparation comes in a 3 oz.tin. (about 100 doses or applications)
About Olfactory Biosciences Corp.
Olfactory Biosciences Corp. continues to lead the field of advanced natural medicines with unique external delivery systems. The company develops topical medicine products can modify behavior or provide relief to common behavior challenges.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements by the Company, statements regarding the NOXO product line, optimism related to the business, expanding ales and other statements in this press release are forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates and projections about the Company's business. and Exchange Commission (SEC) filings under "risk factors" and elsewhere. The forward-looking statements contained in this press release speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.
Richard Stevenson, President
Olfactory Biosciences Corp.
333 E. Lancaster Ave. Suite 317
Wynnewood, PA 19096, USA